Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017091611) ENHANCED CANCER IMMUNOTHERAPY USING ANTIBODY-INTERFERON FUSION MOLECULES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/091611 International Application No.: PCT/US2016/063403
Publication Date: 01.06.2017 International Filing Date: 22.11.2016
IPC:
A61K 38/21 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
21
Interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
IMMUNGENE, INC [US/US]; 480 Constitution Avenue Camarillo, CA 93012, US
Inventors:
GRESSER, Michael; US
STEWARD, Kristopher; US
KHARE, Sanjay; US
GREWAL, Iqbal; US
Agent:
CRANDALL, Craig, A.; US
Priority Data:
62/259,05523.11.2015US
Title (EN) ENHANCED CANCER IMMUNOTHERAPY USING ANTIBODY-INTERFERON FUSION MOLECULES
(FR) AMÉLIORATION DE L'IMMUNOTHÉRAPIE ANTICANCÉREUSE PAR UTILISATION DE MOLÉCULES DE FUSION ANTICORPS-INTERFÉRON
Abstract:
(EN) The present invention relates to fusion molecules designed to improve the efficacy of cancer immunotherapy, comprising one or more IFN molecules attached to an antibody which specifically binds to an immune-checkpoint protein antigen. The fusion molecules of the present invention may be administered alone, or in combination with other non- fused immune-checkpoint protein antigen inhibitors or targeted immunotherapies to treat patients that initially failed to respond to previous anti-cancer therapy.
(FR) La présente invention concerne des molécules de fusion conçues pour améliorer l'efficacité de l'immunothérapie anticancéreuse, comprenant une ou plusieurs molécules d'IFN fixées à un anticorps qui se lie spécifiquement à un antigène d'une protéine de point de contrôle immunitaire. Les molécules de fusion de la présente invention peuvent être administrées seules, ou associées à d'autres inhibiteurs, non fusionnés, de protéines de points de contrôle immunitaires ou à des immunothérapies ciblées, afin de traiter des patients qui n'ont pas répondu à des traitements anticancéreux antérieurs.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)